These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 8251103)

  • 1. Preparing for an FDA audit.
    Barnes D
    Epilepsy Res Suppl; 1993; 10():245-50. PubMed ID: 8251103
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
    Browne TR
    Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
    [No Abstract]   [Full Text] [Related]  

  • 3. Protocol design.
    Wilensky AJ
    Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086
    [No Abstract]   [Full Text] [Related]  

  • 4. External influences on protocol design.
    Spilker B
    Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087
    [No Abstract]   [Full Text] [Related]  

  • 5. European investigational antiepilepsy drug trials.
    Sussman NM
    Epilepsy Res Suppl; 1993; 10():149-55. PubMed ID: 8251090
    [No Abstract]   [Full Text] [Related]  

  • 6. Sources of variability in clinical trials of new drugs for epilepsy.
    Leppik IE
    Epilepsy Res Suppl; 1993; 10():157-66. PubMed ID: 8251091
    [No Abstract]   [Full Text] [Related]  

  • 7. Study population selection.
    Treiman DM
    Epilepsy Res Suppl; 1993; 10():125-35. PubMed ID: 8251088
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of the Institutional Review Board in clinical trials.
    Skolnick BE
    Epilepsy Res Suppl; 1993; 10():193-200. PubMed ID: 8251097
    [No Abstract]   [Full Text] [Related]  

  • 9. Ethical considerations.
    Treiman DM
    Epilepsy Res Suppl; 1993; 10():137-48. PubMed ID: 8251089
    [No Abstract]   [Full Text] [Related]  

  • 10. The domestic drug regulatory process: why time is of the essence.
    Katz R
    Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109
    [No Abstract]   [Full Text] [Related]  

  • 11. Patient recruitment and compliance issues in clinical trials.
    Cramer JA
    Epilepsy Res Suppl; 1993; 10():211-22. PubMed ID: 8251099
    [No Abstract]   [Full Text] [Related]  

  • 12. Obstacles encountered in designing antiepileptic drug trials.
    French JA
    Epilepsy Res Suppl; 1993; 10():81-9. PubMed ID: 8251107
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of the pharmacist in investigational AED trials.
    Graves NM
    Epilepsy Res Suppl; 1993; 10():201-9. PubMed ID: 8251098
    [No Abstract]   [Full Text] [Related]  

  • 14. New clinical trials policy at FDA.
    Vastag B
    Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
    [No Abstract]   [Full Text] [Related]  

  • 15. Progress and deficiencies in the registration of clinical trials.
    Wood AJ
    N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628
    [No Abstract]   [Full Text] [Related]  

  • 16. Closing a loophole in the FDA Amendments Act.
    Turner EH
    Science; 2008 Oct; 322(5898):44-6. PubMed ID: 18832629
    [No Abstract]   [Full Text] [Related]  

  • 17. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

  • 18. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA given new powers over data reporting to national clinical trials registry.
    Roehr B
    BMJ; 2012 Oct; 345():e6629. PubMed ID: 23033375
    [No Abstract]   [Full Text] [Related]  

  • 20. Communicating with the FDA: the "third rail" of a new model for drug development.
    Stanski DR; Orloff JJ
    J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.